Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Beta-lactam + beta-lactamase inhibitor antibiotic

Co-amoxiclav 625mg (Augmentin)

Brand names: Augmentin

Used in: Sepsis Pneumonia Urinary Tract Infection Cellulitis & Skin Infection

Co-amoxiclav combines amoxicillin with clavulanic acid and is used for infections likely to involve beta-lactamase–producing bacteria, including some ENT, respiratory, urinary and skin infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

Adults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-04-30. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

Amoxicillin inhibits bacterial cell-wall synthesis; clavulanic acid inhibits beta-lactamase enzymes, restoring activity against many resistant organisms.

Prescribing in practice

  • Reserve it for indications where added beta-lactamase cover is needed, to limit resistance and adverse effects.
  • It carries a higher risk of cholestatic hepatitis (especially in older patients and with prolonged courses) and of diarrhoea than amoxicillin alone.
  • Contraindicated in penicillin allergy and in a history of co-amoxiclav–associated jaundice/hepatic dysfunction.

Monitoring

Short courses need no routine monitoring; consider liver function with prolonged or repeated use.

Counselling the patient

  • Complete the course; take it with food to reduce stomach upset.
  • Report a rash, yellowing of the skin or eyes, or severe diarrhoea.

Evidence & guidelines

Used per local antimicrobial guidance where beta-lactamase cover is required.

Reference: NICE NG98 AOM; NICE NG120 Sinusitis; PHE Antibiotic Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways